Artificial intelligence is transforming healthcare, unleashing new investment opportunities. From cancer screening to drug discovery, AI promises to augment clinical decision-making and improve care. We’ll explore the surging ecosystem of medical AI innovations, from the emerging tech landscape to practical deployment. But what are the challenges facing real-world implementation? Which applications show the most promise? Join us as we investigate how artificial intelligence can change healthcare for the better while examining what it will take to do it well.

Guests include:

• Bob Nelsen, Co-Founder and Managing Director at Arch Venture Partners
• Daphne Koller, Founder and CEO at insitro
• David Baker, Ph.D., Director at the Institute for Protein Design and Professor of Biochemistry at University of Washington
• Theresa Hajer, Partner and Managing Director of Venture Capital Research at Cambridge Associates

Unseen Upside: Investments Beyond Their Returns is developed in partnership with PRX, an award-winning podcast media company. Cambridge Associates is a global investment firm that works with endowments, foundations, healthcare systems, pension plans, and private clients to implement and manage custom investment portfolios that aim to generate outperformance and maximize their impact on the world. Cambridge Associates delivers a range of portfolio management services, including outsourced CIO, non-discretionary portfolio management, staff extension, and asset class mandates.

Autoimmune diseases like lupus impact over 5 million patients globally, but treatment options remain limited. Now, decoding the once mysterious "dark genome" could bring new therapies. Over 90% of our DNA was once considered "junk"—but we’ve learned this dark matter regulates gene expression and human disease. This episode takes you to the pioneers who are unlocking the dark genome's potential to correct root causes of complex conditions like lupus. We'll chat with those illuminating this uncharted territory and developing novel approaches. Guests include:

• Rosana Kapeller, M.D., Ph.D., Co-Founder, President, & CEO at Rome Therapeutics
• Steve Kafka, General Partner at S32
• Keri Mastrogiacomo, mother of a Lupus patient
• Katherine Cavanagh, Associate Investment Director at Cambridge Associates

Unseen Upside: Investments Beyond Their Returns is developed in partnership with PRX, an award-winning podcast media company. Cambridge Associates is a global investment firm that works with endowments, foundations, healthcare systems, pension plans, and private clients to implement and manage custom investment portfolios that aim to generate outperformance and maximize their impact on the world. Cambridge Associates delivers a range of portfolio management services, including outsourced CIO, non-discretionary portfolio management, staff extension, and asset class mandates.

Obesity is a global health crisis, with over 650 million adults affected worldwide. This drives massive economic and disease burdens. Yet new treatment options like GLP-1 drugs offer hope. This episode analyzes the investment landscape and future of obesity therapeutics, focusing on transformational GLP-1 drugs like Ozempic that curb appetite. Join us as we investigate the promise and challenges of emerging anti-obesity drugs, learn about one patient’s journey taking them, and discover what the future of weight loss medicine could look like. You'll hear from leaders in the space as well as a current patient taking these medications. Guests include:

• Rod Wong, Founder, Managing Partner, and Chief Investment Officer at RTW Investments
• Raymond Stevens, Ph.D., Chief Executive Officer at Structure Therapeutics
• Dean Dimizas, Partner and Managing Director at Cambridge Associates
• Kathleen Mikaelian, Patient

Unseen Upside: Investments Beyond Their Returns is developed in partnership with PRX, an award-winning podcast media company. Cambridge Associates is a global investment firm that works with endowments, foundations, healthcare systems, pension plans, and private clients to implement and manage custom investment portfolios that aim to generate outperformance and maximize their impact on the world. Cambridge Associates delivers a range of portfolio management services, including outsourced CIO, non-discretionary portfolio management, staff extension, and asset class mandates.